(AOF) – The Guerbet share soared 8.72% to 18.46 euros at mid-session after the company specializing in medical imaging delivered its strategic priorities for the year 2023 today. field of diagnostic imaging, where Guerbet achieves almost 90% of its turnover, the aim will be to ramp up sales of the new Elucirem product and strengthen its positions internationally.
In interventional imaging, priority will be given to sales of Lipiodol, a standard in the treatment of liver cancer, with the development of innovative indications. As part of the evolution of its strategy aimed at leveraging key assets, the group plans to gradually withdraw from its micro-catheter activities historically housed within Accurate Medical Therapeutics.
Guerbet finally harbors the hope of creating “a major player in AI dedicated to medical imaging in oncology” after taking a stake in the company Intrasense.
The latter, a specialist in medical imaging software solutions, announced last week the entry into its capital of the Guerbet group up to 39% through a reserved capital increase for a total amount of 8, 8 million euros at an issue price of 0.44 euro per share. Guerbet plans to file soon, on a voluntary basis, a public tender offer for the balance of Intrasense shares, at the same price.